DogTag - Entity Identity Cards
Home / Companies / Xiamen Kingdomway Group

Xiamen Kingdomway Group

Draft - This profile is pending verification.
company_profile Updated: 2025-12-20

Overview

Xiamen Kingdomway Group Company (厦门金达威集团股份有限公司) is a Chinese high-tech enterprise specializing in vitamin and nutraceutical ingredient manufacturing. The company is designated as a National Torch Project enterprise and has been publicly listed on the Shenzhen Stock Exchange since October 2011.

In 2016, Kingdomway expanded into the US consumer supplement market by acquiring Doctor’s Best, a science-based supplement brand.

Key Facts

  • Founded: Prior to 2011
  • Headquarters: Xiamen, Fujian Province, China
  • Stock Code: Shenzhen 002626
  • Listed: October 28, 2011
  • Status: National Torch Project high-tech enterprise
  • Core Business: Vitamin manufacturing, CoQ10 production
  • US Subsidiary: Kingdomway USA Corp.
  • Consumer Brand: Doctor’s Best

Corporate History

Year Event
Pre-2011 Founded in Xiamen, China
2011 Listed on Shenzhen Stock Exchange (002626)
2016 Acquires Doctor’s Best (USA)
2023 Profits decline 67% due to vitamin A and CoQ10 price drops
2024 Record CoQ10 sales recovered; Viactiv acquired via Doctor’s Best

Ownership Structure

Xiamen Kingdomway Group Company (厦门金达威集团)
│   • Stock: Shenzhen 002626
│   • Listed: October 28, 2011
│   • Status: National Torch Project enterprise
│   • HQ: Xiamen, Fujian, China
│
├── Manufacturing Operations (China)
│   • Vitamin production
│   • CoQ10 manufacturing
│   • NMN production
│   • API (Active Pharmaceutical Ingredients)
│
└── Kingdomway USA Corp.
    │   • US holding company
    │
    └── Doctor's Best, Inc. (acquired 2016)
        │   • HQ: Tustin, California
        │   • CEO: Gale Bensussen
        │
        └── Viactiv (acquired 2024)

Business Segments

Ingredient Manufacturing (B2B)

Primary products:

  • Coenzyme Q10 (CoQ10) - Major global producer
  • Vitamin A - Bulk vitamin production
  • NMN (Nicotinamide Mononucleotide) - Anti-aging ingredient
  • Other vitamins and APIs

Consumer Supplements (B2C)

Through Doctor’s Best:

  • Finished supplement products
  • Direct-to-consumer sales
  • E-commerce (iHerb, Amazon)

Financial Performance

2023-2024 Highlights

Year Notes
FY2023 Profits down 67% (vitamin A, CoQ10 price declines)
FY2024 Record CoQ10 sales recovered

Key Drivers:

  • CoQ10 market prices
  • Vitamin A commodity pricing
  • Doctor’s Best consumer sales
  • NMN emerging category

Strategic Acquisitions

Year Target Value Strategic Rationale
2016 Doctor’s Best Undisclosed US market entry, consumer brand
2024 Viactiv (via DRB) $17.2M Women’s health category

Market Position

Competitive Advantages

  1. Vertical Integration: Own ingredient manufacturing
  2. CoQ10 Leadership: Major global CoQ10 producer
  3. US Consumer Brand: Doctor’s Best distribution
  4. Listed Company: Access to capital markets
  5. NMN Pioneer: Early mover in longevity category

Global Presence

Region Operations
China Manufacturing, R&D, headquarters
USA Consumer brand (Doctor’s Best), distribution
Global B2B ingredient sales

Competitors (Ingredient Manufacturing)

Company Focus Region
DSM-Firmenich Vitamins, nutrition Netherlands
BASF Vitamins, nutrition Germany
Zhejiang NHU Vitamins China

Competitors (Consumer Supplements via Doctor’s Best)

Brand Owner Similarity
NOW Foods NOW Health Group ⭐⭐⭐ Value positioning
Jarrow Formulas Jarrow Industries ⭐⭐⭐ Science-based
Life Extension Life Extension Foundation ⭐⭐ Science-based

Data Sources

  1. Bloomberg Company Profile
  2. NutraIngredients - CoQ10 Sales
  3. NutraIngredients - Profit Decline
  4. PitchBook - Doctor’s Best

Generated by DogTag System | Last verified: 2025-12-20

Live Data (Census)

Census data generated: 2025-12-20 09:29

Relationships

  • subsidiary Kingdomway USA Corp.
  • subsidiary Doctor's Best, Inc. since 2016

References